AAPS President David Y.

Related StoriesSausages With Antioxidants From Berries To Prevent CancerScientists discover small molecule that can block growth of BRCA-deficient cancers cellsInner ear damage human brain warnings from nerve cells Research Achievement Award in Pharmacokinetics, Pharmacodynamics, and Drug Fat burning capacity – Sponsored by Aptalis Pharmaceutical Technologies Jashvant D. Unadkat, Ph.D., professor in the Department of Pharmaceutics at the University of Washington, studies how medications are handled by the body – how they are absorbed specifically, metabolized, distributed and excreted.announced that the Stage 3 VELOUR medical trial of aflibercept in sufferers with metastatic colorectal malignancy will continue steadily to completion as planned, without modifications because of efficacy or safety problems. Related StoriesLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. KlegermanAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix We look forward to the final outcomes of the trial, which are anticipated in the second half of 2011 with belief that the mix of aflibercept and FOLFIRI gets the potential to benefit sufferers with this difficult-to-treat disease, stated Tal Zaks, Head of Development, Global Oncology Division, sanofi-aventis..